



amrad corporation limited  
 abn 37 006 614 375  
 576 swan street richmond  
 victoria australia 3121  
 telephone (61 3) 9208 4000  
 facsimile (61 3) 9208 4356  
 http://www.amrad.com.au

82-4867

03 JUL -3 07:21



03024391

**To:** The Securities and Exchange Commission  
**Company:**  
**Fax:** 0011 1 202 942 9624  
**From:** Robyn Fry - Company Secretary  
**Fax:** (+61 3) 9208 4356  
**Date:** 8 July 2003  
**Pages:** 6.  
 Including cover page

SUPPL

*This document and any following pages are intended solely for the named addressee, are confidential and may contain legally privileged information. The copying or distribution of them or any information they contain, by anyone other than the addressee, is prohibited. If you have received this document in error, please let us know by telephone, and then return it by mail to the address above. We shall refund your costs of doing so.*

**FACSIMILE COVER SHEET**

**Amrad Corporation Limited**

Please find attached information being furnished by Amrad Corporation Limited to the Securities and Exchange Commission.

*[Handwritten signature]*

P.P. Robyn Fry  
 General Counsel & Company Secretary

**PROCESSED**  
 JUL 17 2003  
 THOMSON  
 FINANCIAL

*[Handwritten signature]*



amrad corporation limited  
abn 37 006 614 375  
576 swan street richmond  
victoria australia 3121  
telephone (61 3) 9208 4000  
facsimile (61 3) 9208 4352  
<http://www.amrad.com.au>

FILE No.  
82-4867

8 July 2003

Securities and Exchange Commission  
Division of Corporate Finance  
450 Fifth Street NW  
WASHINGTON DC 20549  
USA

Dear Sirs

**AMRAD Corporation Limited**  
**Rule 12g3-2(b) Exemption (File No. 82-4867)**

The enclosed information is being furnished by AMRAD Corporation Limited ("AMRAD") under paragraph (b)(1)(i) of Rule 12g3-2 under the Securities Exchange Act of 1934 ("the Exchange Act"). AMRAD's file number is indicated in the upper right hand corner of each unbound page and the first page of each bound document furnished herewith.

In accordance with paragraphs (b)(4) and (b)(5) of the Rule, the documents furnished herewith are being furnished with the understanding that such documents will not be deemed "filed" with the Securities and Exchange Commission or otherwise subject to the liabilities of Section 18 of the Exchange Act, and that neither this letter nor the furnishings of such documents shall constitute an admission for any purpose that AMRAD is subject to the Exchange Act.

Yours sincerely

**Robyn Fry**  
**General Counsel & Company Secretary**

R51r001

Rule 12g3-2(b) Card Received from the SEC

ISSUER AMRAO Corporation Limited	FILE NO. 82- 4867
-------------------------------------	----------------------

9/4/98

This will advise that the issuer has been added to the list of those foreign private issuers that claim exemption pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Please be further advised that in order to continue to claim this exemption, the issuer must furnish to the Commission, on a timely basis, all information required by Rule 12g3-2(b). This includes all relevant documents since the date of your initial submission. The burden of furnishing such information rests with the issuer, even if it delegates that responsibility to another, and the staff will look to the issuer for compliance. If the issuer is a member of an affiliated or control group which normally prepares reports, press releases, etc., in a single document, a separate report must be submitted for each issuer that claims an exemption under the rule because separate files are maintained for each issuer.

**ALL FUTURE SUBMISSIONS MUST PROMINENTLY INDICATE THE EXEMPTION NUMBER IN THE UPPER RIGHT HAND CORNER OF EACH UNBOUND PAGE AND THE FIRST PAGE OF EACH BOUND DOCUMENT PURSUANT TO THE IDENTIFICATION PROVISIONS OF THE RULE. FAILURE TO SO INDICATE WILL RESULT IN THE SUBMISSION BEING RETURNED TO THE SENDER AND THE SUBMISSION NOT BEING RECORDED, RESULTING IN POSSIBLE LOSS OF THE EXEMPTION.**



**ASX**

AUSTRALIAN STOCK EXCHANGE

Australian Stock Exchange Ltd  
ABN 98 008 624 891  
Exchange Centre  
Level 4, 20 Bridge Street  
Sydney NSW 2000

PO Box H224  
Australia Square  
NSW 1215

Telephone 61 2 9227 0334

Internet <http://www.asx.com.au>  
DX 10427 Stock Exchange Sy

**FACSIMILE**

**Department: COMPANY ANNOUNCEMENTS OFFICE**

**DATE: 08/07/2003**

**TIME: 14:36:56**

**TO: AMRAD CORPORATION LIMITED**

**FAX NO: 03-9208-4356**

**FROM: AUSTRALIAN STOCK EXCHANGE LIMITED - Company Announcements Office**

**SUBJECT: CONFIRMATION OF RECEIPT AND RELEASE OF ANNOUNCEMENT**

**MESSAGE:**

**We confirm the receipt and release to the market of an announcement regarding:**

**Managing Director Resigns**

**PLEASE NOTE:**

**In accordance with Guidance Note 14 of ASX Listing Rules –**

- Use of ASX Online for lodgement of company announcements becomes mandatory from **1 July 2003**
- **Handwritten** and **hand-delivered** company announcements are no longer accepted
- Fee of A\$38.50 (including GST) applies from **1 March 2003** for announcements **faxed** to CAP
- New CAP fax number from **1 March 2003** for announcements sent within Australia is **1900 999 279**

**Nicky Haw.**

---

**From:** ASX.Online@asx.com.au  
**Sent:** Tuesday, 8 July 2003 14:37  
**To:** rfry@amrad.com.au; nhaw@amrad.com.au  
**Subject:** AML - ASX Online e-Lodgement - Confirmation of Release



63203.pdf (11 KB)

ASX confirms the release to the market of Doc ID: 63203 as follows: Release Time: 08-Jul-2003 14:36:49 ASX Code: AML File Name: 63203.pdf Your Announcement Title: Amrad s Managing Director resigns



amrad corporation limited  
abn 37 006 614 375  
576 swan street richmond  
victoria australia 3121  
telephone (61 3) 9208 4320  
facsimile (61 3) 9208 4352  
<http://www.amrad.com.au>

**NEWS RELEASE**  
Tuesday 8 July 2003

**AMRAD MANAGING DIRECTOR RESIGNS**

Amrad Corporation Limited (ASX:AML) today announced Managing Director, Dr Sandra Webb, has resigned from the Company to pursue other interests. The resignation is effective immediately.

Amrad Chairman, Olaf O'Duill, thanked Dr Webb for her valuable contribution to the Company since her appointment in August 2001 and wished her well for future endeavours.

"Dr Webb has been instrumental in delivering some important commercial deals to Amrad, including our recent collaboration with Merck, one of the largest biotechnology collaborations in Australian history, with a potential value of US\$112 million plus royalties," said Mr O'Duill.

"Dr Webb has also overseen the successful divestment of Amrad's Richmond property which was settled late last month," he said.

Mr O'Duill said the Board of Directors would immediately commence an extensive international search for a new Managing Director and in the interim, Amrad Director Bob Moses would assume a caretaker role.

Further information: Olaf O'Duill  
Chairman  
0419 336 608

Anne Hayward  
Investor Relations  
03 9208 4320  
0419 893 922

A biotechnology research & development company



amrad corporation limited  
abn 37 006 614 375  
576 swan street richmond  
victoria australia 3121  
telephone (61 3) 9208 4000  
facsimile (61 3) 9208 4356  
<http://www.amrad.com.au>

**FAXED**  
049703

03 JUL -9 PM 7:21

**To:** The Securities and Exchange Commission  
**Company:**  
**Fax:** 0011 1 202 942 9624  
**From:** Robyn Fry - Company Secretary  
**Fax:** (+61 3) 9208 4356  
**Date:** 4 July 2003  
**Pages:** 6  
Including cover page

*This document and any following pages are intended solely for the named addressee, are confidential and may contain legally privileged information. The copying or distribution of them or any information they contain, by anyone other than the addressee, is prohibited. If you have received this document in error, please let us know by telephone, and then return it by mail to the address above. We shall refund your costs of doing so.*

## FACSIMILE COVER SHEET

### Amrad Corporation Limited

Please find attached information being furnished by Amrad Corporation Limited to the Securities and Exchange Commission.

**Robyn Fry**  
General Counsel & Company Secretary



amrad corporation limited  
abn 37 006 614 375  
576 swan street richmond  
victoria australia 3121  
telephone (61 3) 9208 4000  
facsimile (61 3) 9208 4352  
<http://www.amrad.com.au>

FILE No.  
82-4867

4 July 2003

Securities and Exchange Commission  
Division of Corporate Finance  
450 Fifth Street NW  
WASHINGTON DC 20549  
USA

Dear Sirs

**AMRAD Corporation Limited**  
**Rule 12g3-2(b) Exemption (File No. 82-4867)**

The enclosed information is being furnished by AMRAD Corporation Limited ("AMRAD") under paragraph (b)(1)(i) of Rule 12g3-2 under the Securities Exchange Act of 1934 ("the Exchange Act"). AMRAD's file number is indicated in the upper right hand corner of each unbound page and the first page of each bound document furnished herewith.

In accordance with paragraphs (b)(4) and (b)(5) of the Rule, the documents furnished herewith are being furnished with the understanding that such documents will not be deemed "filed" with the Securities and Exchange Commission or otherwise subject to the liabilities of Section 18 of the Exchange Act, and that neither this letter nor the furnishings of such documents shall constitute an admission for any purpose that AMRAD is subject to the Exchange Act.

Yours sincerely

**Robyn Fry**  
**General Counsel & Company Secretary**

Rfr001

## Rule 12g3-2(b) Card Received from the SEC

ISSUER AMRAO Corporation Limited	FILE NO. 82- 4867
-------------------------------------	----------------------

9/4/98

This will advise that the issuer has been added to the list of those foreign private issuers that claim exemption pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Please be further advised that in order to continue to claim this exemption, the issuer must furnish to the Commission, on a timely basis, all information required by Rule 12g3-2(b). This includes all relevant documents since the date of your initial submission. The burden of furnishing such information rests with the issuer, even if it delegates that responsibility to another, and the staff will look to the issuer for compliance. If the issuer is a member of an affiliated or control group which normally prepares reports, press releases, etc., in a single document, a separate report must be submitted for each issuer that claims an exemption under the rule because separate files are maintained for each issuer.

**ALL FUTURE SUBMISSIONS MUST PROMINENTLY INDICATE THE EXEMPTION NUMBER IN THE UPPER RIGHT HAND CORNER OF EACH UNBOUND PAGE AND THE FIRST PAGE OF EACH BOUND DOCUMENT PURSUANT TO THE IDENTIFICATION PROVISIONS OF THE RULE. FAILURE TO SO INDICATE WILL RESULT IN THE SUBMISSION BEING RETURNED TO THE SENDER AND THE SUBMISSION NOT BEING RECORDED, RESULTING IN POSSIBLE LOSS OF THE EXEMPTION.**



**ASX**

AUSTRALIAN STOCK EXCHANGE

FILE NO.  
62-4867

Australian Stock Exchange Limited  
ABN 98 008 624 691  
Exchange Centre  
Level 4, 20 Bridge Street  
Sydney NSW 2000

PO Box H224  
Australia Square  
NSW 1215

Telephone 61 2 9227 0334

Internet <http://www.asx.com.au>  
DX 10427 Stock Exchange Sydney

**FACSIMILE**

**Department: COMPANY ANNOUNCEMENTS OFFICE**

**DATE:** 04/07/2003

**TIME:** 15:03:49

**TO:** AMRAD CORPORATION LIMITED

**FAX NO:** 03-9208-4356

**FROM:** AUSTRALIAN STOCK EXCHANGE LIMITED - Company Announcements Office

**SUBJECT:** CONFIRMATION OF RECEIPT AND RELEASE OF ANNOUNCEMENT

**MESSAGE:**

We confirm the receipt and release to the market of an announcement regarding:

End of VEGF-B Licensing Deal

**PLEASE NOTE:**

In accordance with Guidance Note 14 of ASX Listing Rules -

- Use of ASX Online for lodgement of company announcements becomes mandatory from 1 July 2003
- Handwritten and hand-delivered company announcements are no longer accepted
- Fee of A\$38.50 (including GST) applies from 1 March 2003 for announcements faxed to CAP
- New CAP fax number from 1 March 2003 for announcements sent within Australia is 1900 999 279

**From:** ASX.Online@asx.com.au  
**Sent:** Friday, 4 July 2003 15:04  
**To:** rfry@amrad.com.au; nhaw@amrad.com.au  
**Subject:** AML - ASX Online e-Lodgement - Confirmation of Release



62735.pdf (14 KB)

ASX confirms the release to the market of Doc ID: 62735 as follows: Release Time: 04-Jul-2003 15:03:48 ASX Code:  
AML File Name: 62735.pdf Your Announcement Title: Amrad announces end of VEGF-B licensing deal



amrad corporation limited  
abn 37 006 614 375  
576 swan street richmond  
victoria australia 3121  
telephone (61 3) 9208 4000  
facsimile (61 3) 9208 4356  
<http://www.amrad.com.au>

Friday, 4 July 2003

### **Amrad announces end of VEGF-B licensing deal**

Amrad (ASX:AML) announced today that it had agreed with Edwards Lifesciences Corporation to end its four-year VEGF-B collaboration. The VEGF-B protein and related patents were licensed to the former cardiovascular unit of Baxter Healthcare Corporation in 1999 for cardiovascular indications only.

Amrad Managing Director, Dr Sandra Webb, said while the decision to end the collaboration was unfortunate, real progress had been made and Amrad had enjoyed a successful and productive relationship with its collaborators.

"The primary objective of the research program was to demonstrate that VEGF-B could stimulate the formation of blood vessels, prior to commencing formal drug development. That has been achieved. Amrad and its collaborators have generated positive pre-clinical data that supports progression of VEGF-B towards clinical studies. However, Edwards informed Amrad that, due to strategic priorities, they will not continue to pursue this opportunity with us," Dr Webb said.

Amrad scientists have resolved significant technical issues, and with a number of collaborators have conducted key animal studies demonstrating proof-of principle. These achievements have triggered several milestone payments to Amrad.

Dr Sandra Webb noted that VEGF-B remains an exciting project for Amrad. "Amrad will continue to push the VEGF-B project forward in a number of directions, including for cardiovascular indications, and will seek partnerships when appropriate. Amrad's recent deal with Merck in respect of new asthma therapeutics confirms our ability to add substantial value to these types of projects and to form valuable partnerships," she said.

#### **About Amrad**

Amrad Corporation Limited is an Australian drug discovery and development based biotechnology company. Amrad's in-house R&D expertise is focused on five priority projects in the areas of allergy and inflammation, anti-infectives and neurological indications. Further information about projects in drug discovery and development can be found at [www.amrad.com.au](http://www.amrad.com.au)

For further information contact:

Dr Sandra Webb  
Managing Director  
Amrad Corporation Limited  
61 (03) 9208 4302